Clinical Operations
Clinical Project ManagementStudy Monitoring and Site ManagementTrial Master File and Document ManagementQuality and Vendor Management SystemsStudy DocumentsRegulatory Affairs
Regulatory StrategyRegulatory WritingAgency Communications and SubmissionsDocument Editorial, QC and SubmissionQC, Review and RedactionLegal RepresentationPharmacovigilanceILAP SubmissionsMedical Communications
Publication PlanningStrategic CommunicationsScientific CommunicationsMedical EducationMedical IllustrationGrant Applications and Project PartnershipServices NST provided to Astex Pharmaceuticals included medical writing for:
Astex Pharmaceuticals, founded in 1999 in Cambridge, UK, specialises in the discovery and development of small-molecule drugs for oncology and central nervous system (CNS) disorders. A pioneer in fragment-based drug discovery (FBDD), Astex employs its proprietary Pyramid™ platform to develop innovative therapies targeting challenging or “intractable” diseases. This approach uses small molecular fragments to design drugs with improved properties, aiming to enhance efficacy and reduce drug development attrition rates.
The company has developed a strong pipeline of proprietary and partnered products. Some notable drugs include Guadecitabine, a DNMT inhibitor for hematologic malignancies, and ASTX660, a dual IAP antagonist for solid tumors and lymphomas. Additionally, Astex collaborates with leading pharmaceutical companies, including Novartis (Kisqali®) and Janssen (Balversa®), to advance its compounds to mark
An important part of Astex’s portfolio is the development of hypomethylating agents for treatment of various diseases, including myelodysplastic syndromes and acute myeloid leukemia. NST was a drug development partner on Astex’s business-critical regulatory writing projects. Projects included clinical protocols, protocol amendments, clinical study reports and safety narratives. The NST team generated high-quality deliverables, largely autonomously, while simplifying complex concepts, drawing on their vast regulatory expertise. NST’s involvement provided valuable writing capacity when Astex’s in-house teams were fully occupied, enabling greater operational efficiency. NST endeavours made an invaluable contribution to Astex’s clinical pipeline.